{"id":{"repo_id":"arizona-thes","oai_identifier":"oai:repository.arizona.edu:10150/662570"},"canonical_url":"https://search.dev.ndltd.org/etd/arizona-thes/oai:repository.arizona.edu:10150/662570","repository":{"repo_id":"arizona-thes","name":"University of Arizona","base_url":"https://repository.arizona.edu/oai/request"},"display":{"title":"Targeting the Central Dogma to Inhibit Nodes of Convergence in Cancer","abstract":"Cancer treatments often target singular oncoproteins in attempt to block one hallmark of cancer and stop tumor growth and progression. However, although these treatments are often initially effective, many cancer patients develop resistance and experience relapse due to redundant signaling or tumor heterogeneity. To avoid resistance mechanisms, cancer treatments must inhibit multiple hallmarks of cancer, and therefore multiple oncogenic signaling programs. One possible way to achieve this is to target nodes of convergence of oncogenic signaling, in which multiple oncogenic pathways depend on one protein for expression or signal proliferation. These nodes can be found within the central dogma processes that drive all cellular function. In this dissertation, this strategy is used to discover inhibitors of nodes involved in transcription, translation, and protein folding of oncogenes and oncoproteins. Targeting nodes of convergence may yield inhibitors that evade resistance mechanisms that plague current cancer therapies and provide superior clinical outcomes for cancer patients.","abstract_html":"Cancer treatments often target singular oncoproteins in attempt to block one hallmark of cancer and stop tumor growth and progression. However, although these treatments are often initially effective, many cancer patients develop resistance and experience relapse due to redundant signaling or tumor heterogeneity. To avoid resistance mechanisms, cancer treatments must inhibit multiple hallmarks of cancer, and therefore multiple oncogenic signaling programs. One possible way to achieve this is to target nodes of convergence of oncogenic signaling, in which multiple oncogenic pathways depend on one protein for expression or signal proliferation. These nodes can be found within the central dogma processes that drive all cellular function. In this dissertation, this strategy is used to discover inhibitors of nodes involved in transcription, translation, and protein folding of oncogenes and oncoproteins. Targeting nodes of convergence may yield inhibitors that evade resistance mechanisms that plague current cancer therapies and provide superior clinical outcomes for cancer patients.","abstract_has_math":false,"creators":["Zerio, Christopher"],"institution":"The University of Arizona.","degree_name":"Ph.D.","degree_level":"doctoral","degree_discipline":"Graduate College","degree_department":null,"school":null,"contributors":[],"advisors":["Chapman, Eli"],"committee_chairs":[],"committee_members":["Zhang, Donna D.","Wang, Jun","Njardarson, Jon T.","Tomasiak, Thomas M."],"year":2021,"date_issued":"2021","date_published":"2021","updated_at":"2026-07-24T00:56:58Z","subjects":["BET","Cancer","Central Dogma","Drug Discovery","eIF4A","Hsp70"],"languages":["en"],"rights":["Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction, presentation (such as public display or performance) of protected items is prohibited except with permission of the author."],"rights_urls":["http://rightsstatements.org/vocab/InC/1.0/"],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10150/662570","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Chapman, Eli"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Zhang, Donna D.","Wang, Jun","Njardarson, Jon T.","Tomasiak, Thomas M."]},{"key":"dc:creator","label":"Author","values":["Zerio, Christopher"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2021-12-14T23:58:03Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2021-12-14T23:58:03Z"]},{"key":"dc:date.issued","label":"Date","values":["2021"]},{"key":"dc:publisher","label":"Institution","values":["The University of Arizona."]},{"key":"dc:type","label":"Dc Type","values":["text","Electronic Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Graduate College","Pharmacology & Toxicology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Arizona"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["BET","Cancer","Central Dogma","Drug Discovery","eIF4A","Hsp70"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction, presentation (such as public display or performance) of protected items is prohibited except with permission of the author."]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://rightsstatements.org/vocab/InC/1.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10150/662570"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Cancer treatments often target singular oncoproteins in attempt to block one hallmark of cancer and stop tumor growth and progression. However, although these treatments are often initially effective, many cancer patients develop resistance and experience relapse due to redundant signaling or tumor heterogeneity. To avoid resistance mechanisms, cancer treatments must inhibit multiple hallmarks of cancer, and therefore multiple oncogenic signaling programs. One possible way to achieve this is to target nodes of convergence of oncogenic signaling, in which multiple oncogenic pathways depend on one protein for expression or signal proliferation. These nodes can be found within the central dogma processes that drive all cellular function. In this dissertation, this strategy is used to discover inhibitors of nodes involved in transcription, translation, and protein folding of oncogenes and oncoproteins. Targeting nodes of convergence may yield inhibitors that evade resistance mechanisms that plague current cancer therapies and provide superior clinical outcomes for cancer patients."]},{"key":"dc:title","label":"Title","values":["Targeting the Central Dogma to Inhibit Nodes of Convergence in Cancer"]}]}],"canonical_facts":{"dc:contributor.advisor":["Chapman, Eli"],"dc:contributor.committeemember":["Zhang, Donna D.","Wang, Jun","Njardarson, Jon T.","Tomasiak, Thomas M."],"dc:creator":["Zerio, Christopher"],"dc:date.accessioned":["2021-12-14T23:58:03Z"],"dc:date.available":["2021-12-14T23:58:03Z"],"dc:date.issued":["2021"],"dc:description.abstract":["Cancer treatments often target singular oncoproteins in attempt to block one hallmark of cancer and stop tumor growth and progression. However, although these treatments are often initially effective, many cancer patients develop resistance and experience relapse due to redundant signaling or tumor heterogeneity. To avoid resistance mechanisms, cancer treatments must inhibit multiple hallmarks of cancer, and therefore multiple oncogenic signaling programs. One possible way to achieve this is to target nodes of convergence of oncogenic signaling, in which multiple oncogenic pathways depend on one protein for expression or signal proliferation. These nodes can be found within the central dogma processes that drive all cellular function. In this dissertation, this strategy is used to discover inhibitors of nodes involved in transcription, translation, and protein folding of oncogenes and oncoproteins. Targeting nodes of convergence may yield inhibitors that evade resistance mechanisms that plague current cancer therapies and provide superior clinical outcomes for cancer patients."],"dc:identifier.uri":["http://hdl.handle.net/10150/662570"],"dc:language.iso":["en"],"dc:publisher":["The University of Arizona."],"dc:rights":["Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction, presentation (such as public display or performance) of protected items is prohibited except with permission of the author."],"dc:rights.uri":["http://rightsstatements.org/vocab/InC/1.0/"],"dc:subject":["BET","Cancer","Central Dogma","Drug Discovery","eIF4A","Hsp70"],"dc:title":["Targeting the Central Dogma to Inhibit Nodes of Convergence in Cancer"],"dc:type":["text","Electronic Dissertation"],"thesis:degree_discipline":["Graduate College","Pharmacology & Toxicology"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Arizona"]},"updated_at":"2026-07-24T00:56:58Z"}